PURPOSE: An IgG1 therapeutic monoclonal antibody showed an increase in acidic or pre-peak by cation exchange chromatography (CEX) at elevated temperatures, though stable at 2-8°C long-term storage in a liquid formulation. Characterization effort was undertaken to elucidate the degradants in CEX pre-peak and effect on biological activity. METHODS: Purified CEX fractions were collected and analyzed by peptide mapping, size exclusion, intact and reduced-alkylated reversed phase techniques. Biophysical characterization, isoelectric focusing and Isoquant analysis were also performed to determine nature of degradants. Bioassay and surface plasmon resonance experiments were performed to determine the impact on biological activity of the degradants. RESULTS: No major degradation due to oxidation, clipping or aggregation was detected; conformational differences between purified fractions observed were not significant. Sialic acid, N-terminal glutamine cyclization and glycation differences contributed to the CEX pre-peak in the mAb control sample; increase in CEX pre-peak at 25°C and higher was caused by additive degradation pathways of deamidation, related isomerization and clipping. CONCLUSIONS: The observed CEX pre-peak increase was caused by multiple degradations, especially deamidation and clipping. This elucidation of degradants in CEX peaks may apply to other therapeutic IgG1 monoclonal antibodies.
PURPOSE: An IgG1 therapeutic monoclonal antibody showed an increase in acidic or pre-peak by cation exchange chromatography (CEX) at elevated temperatures, though stable at 2-8°C long-term storage in a liquid formulation. Characterization effort was undertaken to elucidate the degradants in CEX pre-peak and effect on biological activity. METHODS: Purified CEX fractions were collected and analyzed by peptide mapping, size exclusion, intact and reduced-alkylated reversed phase techniques. Biophysical characterization, isoelectric focusing and Isoquant analysis were also performed to determine nature of degradants. Bioassay and surface plasmon resonance experiments were performed to determine the impact on biological activity of the degradants. RESULTS: No major degradation due to oxidation, clipping or aggregation was detected; conformational differences between purified fractions observed were not significant. Sialic acid, N-terminal glutamine cyclization and glycation differences contributed to the CEX pre-peak in the mAb control sample; increase in CEX pre-peak at 25°C and higher was caused by additive degradation pathways of deamidation, related isomerization and clipping. CONCLUSIONS: The observed CEX pre-peak increase was caused by multiple degradations, especially deamidation and clipping. This elucidation of degradants in CEX peaks may apply to other therapeutic IgG1 monoclonal antibodies.
Authors: M Weitzhandler; D Farnan; J Horvath; J S Rohrer; R W Slingsby; N Avdalovic; C Pohl Journal: J Chromatogr A Date: 1998-12-18 Impact factor: 4.759
Authors: Bei Li; Eric M Gorman; Kimberly D Moore; Todd Williams; Richard L Schowen; Elizabeth M Topp; Ronald T Borchardt Journal: J Pharm Sci Date: 2005-03 Impact factor: 3.534
Authors: Yik Andy Yeung; Maya K Leabman; Jonathan S Marvin; Julia Qiu; Camellia W Adams; Samantha Lien; Melissa A Starovasnik; Henry B Lowman Journal: J Immunol Date: 2009-06-15 Impact factor: 5.422
Authors: Douglas S Rehder; Dirk Chelius; Arnold McAuley; Thomas M Dillon; Gang Xiao; Jill Crouse-Zeineddini; Louisa Vardanyan; Natalie Perico; Venkat Mukku; David N Brems; Masazumi Matsumura; Pavel V Bondarenko Journal: Biochemistry Date: 2008-01-31 Impact factor: 3.162
Authors: Mohammad M Sajadi; George K Lewis; Michael S Seaman; Yongjun Guan; Robert R Redfield; Anthony L DeVico Journal: J Virol Date: 2012-02-29 Impact factor: 5.103
Authors: Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu Journal: MAbs Date: 2018-12-17 Impact factor: 5.857
Authors: Stefan Dengl; Marc Wehmer; Friederike Hesse; Florian Lipsmeier; Oliver Popp; Kurt Lang Journal: Pharm Res Date: 2013-01-16 Impact factor: 4.200
Authors: David Gervais; Darryl King; Patrick Kanda; Nicholas Foote; Lucy Elliott; Phillip Brown; Natacha O Lee; Konstantinos Thalassinos; Claire Pizzey; Robert Rambo; Thomas C Minshull; Mark J Dickman; Stuart Smith Journal: Pharm Res Date: 2015-06-04 Impact factor: 4.200
Authors: Ashaben Patel; Vineet Gupta; John Hickey; Nancy S Nightlinger; Richard S Rogers; Christine Siska; Sangeeta B Joshi; Michael S Seaman; David B Volkin; Bruce A Kerwin Journal: J Pharm Sci Date: 2018-09-01 Impact factor: 3.534
Authors: Danielle M DiCara; Nisana Andersen; Ruby Chan; James A Ernst; Gai Ayalon; Greg A Lazar; Nicholas J Agard; Amy Hilderbrand; Isidro Hötzel Journal: MAbs Date: 2018-09-11 Impact factor: 5.857
Authors: Karin P M Geuijen; Cindy Oppers-Tiemissen; David F Egging; Peter J Simons; Louis Boon; Richard B M Schasfoort; Michel H M Eppink Journal: FEBS Open Bio Date: 2017-09-05 Impact factor: 2.693